Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]-
Female Reproductive System Neoplasm
Sichuan Cancer Hospital and Research InstituteSmall moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Female Reproductive System Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Wenjun Cheng | Phase 3 | BB |
Peg-Rhg-Csf Peking University | Phase 4 | BB |
Adriamycin Amgen | Phase 3 | BB |
Pembrolizumab Sheba Medical Center | Phase 2 | B |
Erythropoietin Amgen | Phase 2 | B |
View all 29 →
Same molecule, other indications
Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →